Synaptogenix (SNPX) Competitors $5.89 -0.60 (-9.24%) As of 08/5/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. STTK, OVID, HYPD, ENLV, KPTI, RANI, LIAN, MRSN, XLO, and AKTXShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Shattuck Labs (STTK), Ovid Therapeutics (OVID), Hyperion DeFi (HYPD), Enlivex Therapeutics (ENLV), Karyopharm Therapeutics (KPTI), Rani Therapeutics (RANI), LianBio (LIAN), Mersana Therapeutics (MRSN), Xilio Therapeutics (XLO), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Shattuck Labs Ovid Therapeutics Hyperion DeFi Enlivex Therapeutics Karyopharm Therapeutics Rani Therapeutics LianBio Mersana Therapeutics Xilio Therapeutics Akari Therapeutics Shattuck Labs (NASDAQ:STTK) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Which has more risk and volatility, STTK or SNPX? Shattuck Labs has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Do institutionals & insiders have more ownership in STTK or SNPX? 58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 12.0% of Shattuck Labs shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, STTK or SNPX? Synaptogenix has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShattuck Labs$5.72M6.86-$75.41M-$1.39-0.59SynaptogenixN/AN/A-$12.77M-$10.08-0.58 Do analysts rate STTK or SNPX? Shattuck Labs presently has a consensus price target of $7.50, indicating a potential upside of 815.97%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.83Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is STTK or SNPX more profitable? Shattuck Labs' return on equity of -79.69% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets Shattuck LabsN/A -79.69% -69.13% Synaptogenix N/A -115.28%-58.31% Does the media refer more to STTK or SNPX? In the previous week, Shattuck Labs had 3 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Shattuck Labs and 0 mentions for Synaptogenix. Shattuck Labs' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score. Company Overall Sentiment Shattuck Labs Neutral Synaptogenix Neutral SummaryShattuck Labs beats Synaptogenix on 11 of the 14 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.19M$3.01B$5.56B$9.47BDividend YieldN/A2.41%4.31%4.17%P/E Ratio-0.5816.5729.3723.99Price / SalesN/A313.98444.7496.71Price / CashN/A42.1735.8458.51Price / Book1.367.818.085.58Net Income-$12.77M-$54.52M$3.26B$265.35M7 Day Performance-12.61%0.41%0.44%-0.07%1 Month Performance-30.71%9.93%4.82%1.76%1 Year Performance71.72%15.18%30.27%25.39% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenixN/A$5.89-9.2%N/A+67.8%$8.19MN/A-0.584Upcoming EarningsGap DownSTTKShattuck Labs3.1538 of 5 stars$0.99+33.3%$7.50+657.6%-73.5%$35.58M$5.72M-0.71100News CoverageGap UpHigh Trading VolumeOVIDOvid Therapeutics4.3787 of 5 stars$0.500.0%$3.13+529.7%-41.8%$35.31M$570K-1.4260Upcoming EarningsHYPDHyperion DeFi0.3213 of 5 stars$5.40-14.1%$2.00-63.0%-92.7%$35.24M$60K-0.0940Upcoming EarningsGap UpENLVEnlivex Therapeutics2.4576 of 5 stars$1.39-6.1%$10.00+619.4%+6.3%$35MN/A-2.1170Short Interest ↑Gap UpKPTIKaryopharm Therapeutics3.6166 of 5 stars$3.88-3.5%$37.40+863.9%-68.0%$34.73M$145.24M-0.29380Upcoming EarningsRANIRani Therapeutics1.9158 of 5 stars$0.55-0.4%$7.33+1,243.1%-78.0%$34.64M$1.03M-0.55110Negative NewsShort Interest ↑LIANLianBioN/A$0.05-2.4%N/A-81.9%$34.47MN/A-0.07110MRSNMersana Therapeutics3.887 of 5 stars$7.04+2.6%$130.00+1,746.6%-82.3%$34.20M$40.50M-0.48150News CoverageUpcoming EarningsXLOXilio Therapeutics3.2051 of 5 stars$0.67+1.4%$4.00+500.3%-27.2%$34.03M$6.34M-0.7970Upcoming EarningsAnalyst ForecastGap UpAKTXAkari Therapeutics3.2476 of 5 stars$1.00-3.2%$5.00+401.5%-73.3%$33.14MN/A0.009Gap Down Related Companies and Tools Related Companies Shattuck Labs Alternatives Ovid Therapeutics Alternatives Hyperion DeFi Alternatives Enlivex Therapeutics Alternatives Karyopharm Therapeutics Alternatives Rani Therapeutics Alternatives LianBio Alternatives Mersana Therapeutics Alternatives Xilio Therapeutics Alternatives Akari Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPX Stock Alerts